SOPHiA DDM™ Myeloid Solution
Expand the scope of myeloid neoplasms management
SOPHiA DDM™ Myeloid Solution is a ready-to-use genomic application, designed to empower clinical researchers to make better-informed decisions in the assessment of different blood cancer disorders.
This comprehensive solution accurately covers 30 genes associated with myelodysplastic syndromes, myeloproliferative neoplasms, and leukemia. The application combines a capture-based target enrichment kit with the advanced analytical capabilities of the SOPHiA DDM™ platform, providing high-quality and reproducible data through a streamlined workflow from sample to report.
Ready-to-use target enriched library in just 2 days
Data analysis from FASTQ files in as little as 4 hours
Accurate detection and annotation of challenging variants, such as SNVs, Indels, CNVs, fusions, FLT3 internal tandem duplications in one unique experiment
Streamline interpretation with the SOPHiA DDM™ intuitive variant filters, algorithm-supported variant classification with OncoPortal™ to obtain the latest scientific evidence on all the relevant variants
Have access to one of the largest networks of connected healthcare institutions within SOPHiA DDM™, to gain and share knowledge on relevant variants
Confidently asses complex blood cancer variants
Molecular profiling by next-generation sequencing has introduced a paradigm shift in investigating the pathogenic variants causing different blood cancer disorders. Through a streamlined, customizable, and scalable NGS-based workflow, SOPHiA DDM™ Myeloid Solution reduces turnaround time and improves the efficiency of assessing complex variants associated with different blood cancers with uniform coverage of DNA alterations (e.g., CALR, CEBPA, ASXL1, FLT3, including internal tandem duplications) aligned with recent guidelines.
Dedicated features to ease variant interpretation
The SOPHiA DDM™ platform features intuitive variant filters and prioritization options to streamline the interpretation process and greatly reduce turnaround time.
- Virtual Panels to limit the interpretation to a subset of genes
- Cascading Filters to enable user-created custom filtering strategies for quicker identification of relevant variants
- OncoPortal™ to support decisions based on the Jax-CKB™, CAP, ASCO, AMP and other data sources
“We were able to remove recurring artifacts and PCR errors. The solution correctly called Indels and large deletions, which were incorrectly identified by a previous pipeline, and we gained the ability to detect large insertions in FLT3 without using additional tools – this made the move a no-brainer.”
Olena Kis, PhD
Associate Director, Molecular Pathology
|Diseases Covered||Myelodysplastic syndromes, myeloproliferative neoplasms, and leukemia|
|Genes||30 genes (10 with complete coding sequences.) Panel:
ABL1, ASXL1, BRAF, CALR, CBL, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2, KIT KRAS, MPL, NPM1, NRAS, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, TET2, TP53, U2AF1, WT1, ZRSR2
|Key Biomarkers||CEBPA, ASXL1, CALR, FLT3 including internal tandem duplications|
|Target Region Size||48 Kb|
|Sample Type||Blood and bone marrow|
|DNA Input Amount||50 ng DNA|
|Library Preparation Time||2 days|
|Analysis Time From FASTQ||From 4 hours|
Please fill out the form below to get in touch
SOPHiA DDM™ for Blood Cancers
Our future-proof end-to-end solutions allow detection and characterization of complex genomic variants associated with different blood cancers.
SOPHiA DDM™ for Solid Tumors
From targeted to comprehensive genomic profiling, our solutions support healthcare professionals in their journey to analyze solid tumors.
SOPHiA DDM™ for Hereditary Cancers
Our solutions help reduce time to confidently assess multiple types of challenging genetic variants that indicate predisposition to inherited cancers.